ALGN vs COO
Align Technology and Cooper Companies, side by side.
Prices and company dataas of yesterday's close
- ALGNKeepin the past month+21%
Align rose 21% over the past month, far more than other health care stocks (up 6.5%), but two fewer analysts rate it a buy than three months ago.
- COOSell somein the past month+16%
Cooper Companies rose 16% over the past month, far more than other health care stocks (up 6.5%), and four fewer analysts rate it a buy than three months ago.
Percent return
- ALGN+19.09%
- COO−12.28%
Nov 11, 2025 to Nov 11, 2026
Where they differ
- Company size: ALGN $12.5B, COO $13.8B.
- Sales growth, 1 yr: ALGN +4.4%, COO +4.7%. COO is ahead.
- Price for $1 of next year's profit: ALGN $14, COO $14.
- Profit per $1 of sales: ALGN 19¢, COO 13¢. ALGN is ahead.
- Cash minus debt: ALGN +$1.03B, COO −$2.65B. ALGN is ahead.
- Price change, 1 yr: ALGN +19%, COO −12%. ALGN is ahead. S&P 500 +12%.
- How much the price swings: ALGN 37%, COO 41%. ALGN is ahead.
| Measure | ALGNAlign Technology | COOCooper Companies |
|---|---|---|
| Price and returns | ||
| Price | $172.08 | $62.93 |
| Today | −1.25% | Best in this row: −1.01% |
| 1 month | Best in this row: +20.58% | +15.74% |
| 3 months | Best in this row: −0.51% | −18.09% |
| This year | Best in this row: +10.20% | −23.22% |
| 1 year | Best in this row: +19.09% | −12.28% |
| 5 years | −74.91% | Best in this row: −38.71% |
| From 52-week high | −12.9% | −25.4% |
| How much it swings (90 days) | Best in this row: 37% | 41% |
| Valuation | ||
| Market value | $12.5B | $13.8B |
| Price vs last year's earnings | Best in this row: 29.3× | 60.1× |
| Price vs next year's expected earnings | 13.9× | Best in this row: 13.7× |
| Price vs earnings, adjusted for growth | 1.60× | Best in this row: 1.42× |
| Price to sales | 2.8× | Best in this row: 2.8× |
| Price vs cash it brings in | 18.1× | Best in this row: 17.5× |
| Company value vs operating profit | Best in this row: 11.1× | 15.6× |
| Price vs earnings, against its own past (0 = cheapest) | Best in this row: 70 | 92 |
| Growth | ||
| Revenue growth, 1 year | +4.4% | Best in this row: +4.7% |
| Revenue growth a year, last 3 years | +2.6% | Best in this row: +7.3% |
| Earnings per share growth, last year | Best in this row: +8.7% | −42.6% |
| Earnings per share growth expected next year | Best in this row: +10.4% | +3.3% |
| Profitability | ||
| Kept from sales after making the product | Best in this row: 71.3% | 65.9% |
| Kept as operating profit | Best in this row: 19.4% | 12.9% |
| Kept as final profit | 11.8% | Best in this row: 13.5% |
| Kept as spare cash | 15.6% | Best in this row: 16.0% |
| Profit on shareholders' money | Best in this row: 11.9% | 6.8% |
| Profit on all money put in | Best in this row: 18.9% | 5.0% |
| Balance sheet | ||
| Net cash (cash minus debt) | Best in this row: $1.03B | −$2.65B |
| Debt for each $1 of shareholders' money | Best in this row: 0.03× | 0.34× |
| Short-term assets per $1 of bills due | Best in this row: 1.42× | 1.22× |
| Our readPro | ||
| Our call | Keep | Sell some |
| Why | Align rose 21% over the past month, far more than other health care stocks (up 6.5%), but two fewer analysts rate it a buy than three months ago. | Cooper Companies rose 16% over the past month, far more than other health care stocks (up 6.5%), and four fewer analysts rate it a buy than three months ago. |
| Where the price sits | in the full report | in the full report |
| Our overall score (out of 100) | Best in this row: 66 | 51 |
| Our value score | Best in this row: 80 | 59 |
| Our growth score | Best in this row: 51 | 32 |
| Our quality score | Best in this row: 71 | 59 |
| Our price trend score | Best in this row: 70 | 67 |
| Earnings and analysts | ||
| Next earnings | – | Dec 3AMCin 21 days |
| Analyst consensus | Buy | Hold |
| To average analyst target | Best in this row: +9.2% | +3.0% |
| Average analyst target | $187.89 | $64.83 |
| Analysts rating it a buy | Best in this row: 50% | 35% |
| Buy ratings added, 3 months | Best in this row: −2 | −4 |
| Analysts covering | 11 | 14 |
ALGN: more analyst upside and wider profit margins
Our pick of these: Align Technology
+9.2% to the average analyst target, vs +3.0%
ALGN +9.2%, COO +3.0%.Keeps 19.4% of sales as operating profit, vs 12.9%
ALGN 19.4%, COO 12.9%.1-year return +19.1% vs −12.3%, S&P 500 +12.4%
ALGN +19.1%, COO −12.3%.Where it loses: COO has a lower P/E per point of growth, 2.89 vs 3.15
Cover this stock to see the full report
The call, its reasons and what would change it are free for everyone. The price zones, the whole brief and how the call has moved come with covering a stock. Use one of your three covered slots, or go Pro for every stock.
Prices as of yesterday, 3:59 PM ET. A view, not advice.